User contributions
Jump to navigation
Jump to search
- 18:59, 10 August 2023 diff hist +1 Multiple myeloma, induction →Dara-RVd{{#subobject:5coba5|Regimen=1}}
- 16:03, 10 August 2023 diff hist +638 Multiple myeloma, induction →Synopsis
- 22:18, 8 August 2023 diff hist +1,956 Multiple myeloma, relapsed-refractory →Thalidomide monotherapy {{#subobject:ff02e1|Regimen=1}}
- 21:49, 8 August 2023 diff hist +3,033 Multiple myeloma, consolidation and maintenance →Melphalan, then auto HSCT {{#subobject:263542|Regimen=1}}
- 21:45, 8 August 2023 diff hist -2,975 Multiple myeloma, consolidation and maintenance →Bortezomib & Melphalan, then auto HSCT {{#subobject:9c28bc|Regimen=1}}
- 21:44, 8 August 2023 diff hist +2,976 Multiple myeloma, consolidation and maintenance →Bortezomib & Melphalan, then auto HSCT {{#subobject:9c28bc|Regimen=1}}
- 21:15, 8 August 2023 diff hist +1,925 Multiple myeloma, induction Tag: Visual edit: Switched
- 22:52, 14 December 2020 diff hist +1 Multiple myeloma, relapsed-refractory →KRD-PACE {{#subobject:0072na|Regimen=1}}
- 22:52, 14 December 2020 diff hist +118 Multiple myeloma, relapsed-refractory →KRD-PACE {{#subobject:0072na|Regimen=1}}
- 22:51, 14 December 2020 diff hist 0 Multiple myeloma, relapsed-refractory →KRD-PACE {{#subobject:0072na|Regimen=1}}
- 22:50, 14 December 2020 diff hist 0 Multiple myeloma, relapsed-refractory →KRD-PACE {{#subobject:0072na|Regimen=1}}
- 22:49, 14 December 2020 diff hist 0 Multiple myeloma, relapsed-refractory →KRD-PACE {{#subobject:0072na|Regimen=1}}
- 22:49, 14 December 2020 diff hist +2 Multiple myeloma, relapsed-refractory →KRD-PACE {{#subobject:0072na|Regimen=1}}
- 22:48, 14 December 2020 diff hist +3,649 Multiple myeloma, relapsed-refractory →Relapsed or refractory, non-randomized or retrospective data
- 19:37, 18 May 2018 diff hist -388 Multiple myeloma →Bortezomib-HyperCAD
- 19:36, 18 May 2018 diff hist +2,353 Multiple myeloma →Bortezomib-HyperCAD
- 19:31, 18 May 2018 diff hist +26 Multiple myeloma →Relapsed or refractory, non-randomized or retrospective data
- 19:28, 18 May 2018 diff hist +1,962 Multiple myeloma →Hyper-CVAD {{#subobject:0df285|Regimen=1}}
- 02:23, 18 December 2015 diff hist +1,011 Classical Hodgkin lymphoma →Relapsed/refractory
- 19:07, 11 August 2014 diff hist -14 Transplant conditioning regimens →DHAP --> BEAC & Transplant
- 19:00, 11 August 2014 diff hist +2,195 Transplant conditioning regimens →Autologous (auto) stem cell transplant
- 16:54, 21 March 2014 diff hist +1,363 Urothelial carcinoma
- 04:11, 25 February 2014 diff hist +9 Prostate cancer →Enzalutamide (Xtandi)
- 23:47, 24 February 2014 diff hist +1,671 Gastric cancer
- 23:18, 24 February 2014 diff hist +1,108 Gastric cancer →Perioperative chemotherapy
- 22:28, 24 February 2014 diff hist -2 Prostate cancer →Enzalutamide (Xtandi)
- 22:28, 24 February 2014 diff hist -244 Prostate cancer →Enzalutamide (Xtandi)
- 22:27, 24 February 2014 diff hist +644 Prostate cancer →Enzalutamide (Xtandi)
- 23:03, 10 January 2014 diff hist +1,081 Immune thrombocytopenia →Relapsed/Refractory
- 18:14, 27 September 2013 diff hist 0 Small cell lung cancer →Ipilimumab + Paclitaxel & Carboplatin
- 18:13, 27 September 2013 diff hist -2 Prostate cancer →Regimen
- 18:12, 27 September 2013 diff hist +1,117 Prostate cancer →Immunotherapy for metastatic castrate-resistant disease
- 17:26, 27 September 2013 diff hist -6 Small cell lung cancer →Ipilimumab + Paclitaxel & Carboplatin
- 17:25, 27 September 2013 diff hist +1,593 Small cell lung cancer →Extensive stage
- 22:40, 24 July 2013 diff hist +1,164 Hairy cell leukemia →Untreated
- 22:17, 24 July 2013 diff hist +970 Hairy cell leukemia
- 04:12, 4 July 2013 diff hist -1 Lapuleucel-T (DN24-02)
- 04:11, 4 July 2013 diff hist +1,358 N Lapuleucel-T (DN24-02) Created page with "==General information== Class/mechanism: Autologous cellular immunotherapy, designed to stimulate a response against HER2/Neu receptor. Autologous peripheral blood mononuclear..."
- 19:58, 3 July 2013 diff hist +1,146 N Inotuzumab ozogamicin (Besponsa) Created page with "'''In clinical trials'''. ==General information== Class/mechanism: Antibody targeting CD22, conjugated with a cytotoxic, antitumor antibiotic (calicheamicin). Inotuzumab demo..."
- 19:42, 3 July 2013 diff hist +37 Pathology →General pathology
- 06:12, 1 July 2013 diff hist +797 Acute myeloid leukemia
- 21:57, 8 June 2013 diff hist +1,643 Aggressive Non-Hodgkin lymphoma →DLBCL, Relapsed/Refractory
- 16:38, 31 May 2013 diff hist +946 Penile cancer →Metastatic or unresectable disease
- 22:17, 30 May 2013 diff hist +1,259 Penile cancer →Metastatic or unresectable disease
- 22:08, 30 May 2013 diff hist +1,209 Penile cancer
- 02:50, 23 May 2013 diff hist +2,315 N Penile cancer Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' Is th..."
- 02:20, 23 May 2013 diff hist +22 Main Page
- 22:00, 22 May 2013 diff hist +1,358 T-cell lymphoma →Extranodal NK/T-cell lymphoma, nasal type
- 21:31, 22 May 2013 diff hist +909 T-cell lymphoma →DeVIC & Concurrent RT
- 21:25, 22 May 2013 diff hist +230 T-cell lymphoma →DeVIC & Concurrent RT